Ariad Pharmaceuticals PT Raised to $21.00 at Goldman Sachs Group Inc. (ARIA)
Investment analysts at Goldman Sachs Group Inc. boosted their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $20.00 to $21.00 in a note issued to investors on Wednesday, StockRatingsNetwork reports. Goldman Sachs Group Inc.’s target price would suggest a potential upside of 0.67% from the stock’s previous close.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 1.04% on Wednesday, hitting $20.86. 1,927,095 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a one year low of $15.35 and a one year high of $25.40. The stock’s 50-day moving average is $19.31 and its 200-day moving average is $18.78. The company’s market cap is $3.861 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was up 4302.5% on a year-over-year basis. Analysts expect that Ariad Pharmaceuticals will post $-1.63 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on ARIA. Analysts at RBC Capital reiterated an “outperform” rating on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a research note to investors on Friday, September 6th. They now have a $28.00 price target on the stock. Separately, analysts at Chardan Capital initiated coverage on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a research note to investors on Wednesday, September 4th. They set a “buy” rating and a $28.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a research note to investors on Monday, August 19th.
Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.04.
In other Ariad Pharmaceuticals news, Insider Timothy P. Clackson sold 8,449 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $22.00, for a total value of $185,878.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.